Gsk (GLAXF) Cash from Operations (2009 - 2026)

Gsk's Cash from Operations history runs 18 years deep, the most recent figure standing at 1820040839.39 for Q1 2026.

• In Q1 2026, Cash from Operations rose 11.07% year-over-year to 1820040839.39; the TTM figure through Mar 2026 stood at 8999609286.41 (changed 0.03% YoY), while the FY2025 annual figure was 10206588510.3, up 21.83% from the prior year.
• Cash from Operations was 1820040839.39 for Q1 2026 at Gsk, down from 1977957137.12 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 3563001106.15 in Q4 2024 to a low of 348851232.01 in Q1 2023.
• Historically, Cash from Operations has averaged 2158179740.85 across 5 years, with a median of 1977957137.12 in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations jumped 647.32% in 2022, then tumbled 89.77% in 2023.
• A 5-year view of Cash from Operations shows it stood at 2868982673.51 in 2022, then retreated by 17.5% to 2366876645.43 in 2023, then surged by 50.54% to 3563001106.15 in 2024, then slumped by 44.49% to 1977957137.12 in 2025, then declined by 7.98% to 1820040839.39 in 2026.
• The last three Cash from Operations figures came in at 1820040839.39 (Q1 2026), 1977957137.12 (Q4 2025), and 1638610203.75 (Q1 2025), per Business Quant data.